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ABSTRACT
FEN1, a key participant in DNA replication and
repair, is the major human flap endonuclease that
recognizes and cleaves flap DNA structures.
Deficiencies in FEN1 function or deletion of the
fen1 gene have profound biological effects,
including the suppression of repair of DNA
damage incurred from the action of various
genotoxic agents. Given the importance of FEN1 in
resolving abnormal DNA structures, inhibitors of the
enzyme carry a potential as enhancers of
DNA-interactive anticancer drugs. To facilitate the
studies of FEN1 activity and the search for novel
inhibitors, we developed a pair of complementary-
readout homogeneous assays utilizing fluorogenic
donor/quencher and AlphaScreen chemilumines-
cence strategies. A previously reported FEN1
inhibitor 3-hydroxy-5-methyl-1-phenylthieno[2,3-d]
pyrimidine-2,4(1H,3H)-dione displayed equal
potency in the new assays, in agreement with its
published IC50. The assays were optimized to a
low 4ml volume and used to investigate a set of
small molecules, leading to the identification of
previously-unreported FEN1 inhibitors, among
which aurintricarboxylic acid and NSC-13755 (an
arylstibonic derivative) displayed submicromolar
potency (average IC50 of 0.59 and 0.93mM, respect-
ively). The availability of these simple complemen-
tary assays obviates the need for undesirable
radiotracer-based assays and should facilitate
efforts to develop novel inhibitors for this key bio-
logical target.
INTRODUCTION
Human ﬂap endonuclease 1 (FEN1) is an efﬁcient
structure-speciﬁc enzyme that recognizes and cleaves a
50-unannealed DNA ﬂap. It belongs to the RAD2 family
of nucleases that metabolize DNA and is highly conserved
in prokaryotes and eukaryotes (1–3). FEN1 is a key
enzyme in DNA replication, repair and maintenance of
genomic stability. 50-ﬂap removal by FEN1 is critical for
Okazaki fragment processing during lagging strand DNA
synthesis (4), long-patch base excision repair (LP BER) (5)
and regulation of recombination [reviewed in (6)]. The
importance of FEN1 in maintaining genomic stability is
demonstrated by the phenotypes of cells deﬁcient for the
protein. Deletion of the yeast FEN1 gene, rad27, results in
an increased frequency of short DNA (3–32bp) repeats,
micro- and mini-satellite formation, trinucleotide repeat
expansion, spontaneous recombination events and a
severe growth defect in association with cell cycle arrest
in late S/G2 phase (6). Mice carrying a homozygous null
genotype (fen1
 / ) exhibit an early embryonic lethality
(E4.5), indicating a requirement for normal development
(7,8). Cells from fen1
 /  blastocysts show increased apop-
totic cell death after ionizing radiation treatment (8), and
chicken cells lacking the fen1 gene are hypersensitive to
DNA alkylating agents, e.g. methylmethane sulfonate
(MMS) and N-methyl-N0-nitro-N-nitrosoguanidine
(MNNG), as well as hydrogen peroxide (9). However, re-
sistance to oxidative stress is only mildly affected in rad27-
deletion yeast (10). These results indicate FEN1 deﬁciency
leads to failure to repair DNA lesions generated by DNA
alkylating agents, but the story is less clear with oxidizing
compounds.
Several structure-speciﬁc 50-ﬂap substrates have been
identiﬁed for FEN1. The nick-ﬂap, a ﬂap with its base
adjacent to an upstream primer, is removed by FEN1,
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The double-ﬂap with a 1-nt 30-tail structure is also cleaved
by FEN1 to generate only a single product, a nick that can
be directly ligated. A substrate with this structure is
optimal for FEN1 homologs of archeabacteria (13),
yeast (14) and human (15) and is thought to be
produced naturally in vivo as an intermediate of strand
displacement DNA synthesis. The double-ﬂap is bound
with higher afﬁnity, and cleaved with increased efﬁciency
and speciﬁcity, compared to the nick-ﬂap (6). A 50-double-
ﬂap with a 10-nt 30-tail is also efﬁciently cleaved by FEN1
in vitro and such double-ﬂap structures may form during
some homologous recombination (HR) events (16).
FEN1 is found to be increased in many human cancers,
including lung cancer (17,18), gastric cancer (19), prostate
cancer (20,21), pancreatic cancer (22), brain cancer (17,23)
and breast cancer (24). These results suggest that FEN1
may, in part, be involved in tumor progression and devel-
opment. In fact, FEN1 gene expression has been shown to
be induced during cell proliferation and down-regulated
during cell differentiation (25). In particular, elevation of
FEN1 in hormone refractory human prostate cancer cells
correlates with resistance to various anticancer agents,
including ionizing radiation, doxorubicin, paclitaxel and
vinblastine (26). Conversely, down-regulation of FEN1
has been shown to sensitize human glioblastoma cells to
MMS, and the clinical drugs temozolomide (TMZ) and
cisplatin (17). These studies suggest that the levels of
FEN1 expression inﬂuence cancer cell function as it
relates to proliferation potential, survival and apoptosis.
Most anticancer agents used in the clinic today intro-
duce cytotoxic DNA lesions to destroy rapidly dividing
cells (27). Cells have evolved a compilation of highly
effective, conserved DNA repair systems to protect
against both endogenous and exogenous DNA damage.
However, these systems also process DNA lesions
generated by anticancer drugs. Thus, BER, for example,
has been shown to be an important factor in determining
responsiveness to DNA-interactive drugs, such as
alkylating agents (e.g. TMZ) and anti-metabolites (e.g.
5-ﬂuorouracil and certain nucleoside analogs) (28).
Moreover, tumor resistance to alkylating agents is
common due to the increased levels of speciﬁc DNA
repair enzymes (29). Human bladder carcinoma cells
that lack ﬂap endonuclease activity due to an amino
acid point mutation in FEN1 (D181A) are highly suscep-
tible to killing by the alkylating agent MMS (30), a
compound that generates DNA substrates primarily pro-
cessed by BER (31). Indeed, reduced FEN1 levels increase
sensitivity of human cancer cells to the cytotoxicity of
different alkylating agents (17). Moreover, it was
recently shown that FEN1 can be a target in the selective
killing of cancer cells via a mechanism involving ‘synthetic
lethality’ (32). RAD54B-deﬁcient human colorectal cancer
cells, which are defective in HR, exhibit a proliferation
defect and increased cellular cytotoxicity when FEN1 ex-
pression is reduced (33). The principle of synthetic lethal-
ity has been brought to the forefront and perhaps has been
best exploited in the case of PARP-1 inhibitors, which
promote the killing of BRCA-deﬁcient (HR-defective)
cancer cells (34,35). Therefore, FEN1 is a logical target
for inactivation during both genetic-based and combina-
torial anticancer treatment paradigms, and there is a need
to develop functionally effective small molecule FEN1
inhibitors.
To facilitate the discovery and development of FEN1
inhibitors, a robust and sensitive method for monitoring
its catalytic activity is needed. Traditionally, in vitro
studies of FEN1 have utilized radiolabeled substrate con-
structs in conjunction with gel electrophoretic separation,
a method not suitable for large-scale testing of inhibitors.
Recently, an assay based on ﬂuorescently labeled nucleo-
tides was used in a screen to indentify inhibitors of
FEN1 (36). In this system, 50-end TAMRA
(6-carboxytetramethylrhodamine) and 30-end VIC (propri-
etary ﬂuorescent dye excited at 488nm, peak emission at
552nm) labeled oligodeoxynucleotides were annealed
together with a 30-end BHQ (Black Hole Quencher, a
non-ﬂuorescent dark quencher) labeled strand to create
a FEN1 substrate. VIC and BHQ were in close proximity,
and the signal remained quenched upon excitation. In the
presence of the enzyme, the VIC dye-carrying strand was
cleaved off, leading to an increase in the VIC ﬂuorescence.
However, the substrate was unnecessarily complicated by
the use of three dye labels and its use of ‘green’ ﬂuores-
cence detection made it susceptible to autoﬂuorescence
from small molecule library members (37). Here, we
describe the development of a pair of complementary-
readout miniaturized homogeneous assays for FEN1
activity utilizing red-shifted ﬂuorogenic donor/quencher
and AlphaScreen chemiluminescence strategies. Testing a
set of small molecules in these assays led to the identiﬁca-
tion of new FEN1 inhibitors.
MATERIALS AND METHODS
Reagents
An amount of 1M Tris–HCl, Tween-20, EDTA, NaCl,
MgCl2 and dithiothreitol (DTT) were purchased from
Sigma–Aldrich. Dimethyl sulfoxide (DMSO, certiﬁed
ACS grade) was obtained from Fisher, Inc. Black and
white solid-bottom 384-well and 1536-well plates were
purchased from Greiner Bio One (Monroe, NC, USA).
The AlphaScreen FITC/streptavidin detection kit was
from PerkinElmer Life and Analytical Sciences
(Waltham, MA, USA).
Small molecule inhibitors
Arylstibonic inhibitors (NSC 13744, NSC 13793, NSC
15596 and NSC 13755) were obtained from the National
Cancer Institute Developmental Therapeutics Program
Natural Products Repository, while aurintricarboxylic
acid (ATA) was purchased from Sigma-Aldrich.
3-hydroxy-5-methyl-1-phenylthieno[2,3-d]pyrimidin-
e-2,4(1H,3H)-dione (hereafter PTPD) was synthesized ac-
cording to reported methods (36). The compounds were
initially prepared as 10mM DMSO stock solutions and
were arrayed for testing as serial 2-fold dilutions at 7ml
per well in 1536-well Greiner polypropylene compound
plates following previously described protocols (38).
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Recombinant, untagged human FEN1 protein was
puriﬁed from bacteria as previously described (1).
Oligodeoxynucleotide substrates
All oligodeoxynucleotides were purchased from Biosearch
Technologies, Inc., (Novato, CA, USA). The
double-stranded DNA substrate containing a double ﬂap
region used in the ﬂuorogenic assay was prepared from
three oligodeoxynucleotides: quencher (50-CAC GTT
GAC TAC CGC TCA ATC CTG ACG AAC ACA
TC-BHQ-2), ﬂap (50-TAMRA-GA TGT CAA GCA
GTC CTA ACT TTG AGG CAG AGT CCG C) and
template (50-GC GGA CTC TGC CTC AAG ACG
GTA GTC AAC GTG-30) strands by a standard anneal-
ing procedure (see below). For the AlphaScreen assay, a
substrate containing a single ﬂap strand was prepared
from three oligodeoxynucleotides: adjacent (50
biotin-TCA CCC TCG TAC GAC TCA), ﬂap
(50-FITC-TTT TTT TTT TTT ATT CAT CAA CTG
ACA TCT CCT AC) and template (50-GT AGG AGA
TGT CAG TTG ATG AAT TGA GTC GTA CGA
GGG TGA-30) strands by a standard annealing procedure
(see below). Annealing of the oligodeoxynucleotide com-
ponents was performed in 50mM Tris pH 8.0, 100mM
KCl, 5mM MgCl2 by ﬁrst incubating the mixture at
95 C for 5min, followed by gradual cooling to room tem-
perature. The annealed double-stranded DNA substrates
were then stored at  20 Ca s5 0 mM stocks.
High-resolution melting experiments that measure the
increase in ﬂuorescence intensity (corresponding to the
relief in quenching) upon temperature-induced separation
of the donor and quencher strands of the double-ﬂap
DNA substrate at 50nM in the Roche LightCycler 480
instrument yielded a Tm of 53.5 C from a sextuplicate
measurement (data not shown). While there is likely a
fraction of the two ﬂap strands which remain separated,
the presence of a clear melting transition at 53.5 C
conﬁrms that the present substrate exists in a predomin-
antly quenched (annealed) state at room temperature.
Fluorogenic assay in 384-well format
The FEN1 ﬂuorogenic assay was carried out in a 40ml
reaction mixture in 50mM Tris–HCl pH 8.0, 10mM
MgCl2, 1mM DTT and 0.01% Tween-20. Speciﬁcally,
30ml of either FEN1 at appropriate concentration or
buffer (no-enzyme control) was pipetted into a 384-well
plate; subsequently, 10ml of substrate was added to start
the reaction. Kinetic ﬂuorescence data were collected on
ViewLux high-throughput CCD imager (Perkin Elmer,
Waltham, MA, USA) equipped with standard optics (ex-
citation ﬁlter 525nm and emission ﬁlter 598nm).
Assay miniaturization in 1536-well format
Three microliters of reagent (buffer as negative control
and FEN1 in the remainder of the plate) was dispensed
by a BioRPTR nanoliter dispenser (Beckman Coulter Inc.,
Fullerton, CA) into a 1536-well solid-bottom black plate.
Where applicable, inhibitor compounds were delivered as
23-nl aliquots of DMSO solutions via pintool transfer as
described elsewhere (38,39); vehicle-only control consisted
of 23nl DMSO. The plate was incubated for 15min at
room temperature, and then 1ml of substrate (50nM
ﬁnal concentration) was added to initiate the reaction.
The plate was transferred into ViewLux reader for
kinetic ﬂuorescence data collection; there was  50s time
lapse between the end of the substrate dispense and the
commencement of the ﬂuorescence kinetic read. IC50
values were calculated from the dose-response curve ﬁts
generated within GraphPad Prism using the ﬂuorescence
intensity change over the ﬁrst 20min of data collection
and relating it to uninhibited and no-enzyme controls.
AlphaScreen-based assay development and optimization
Beads’ binding capacity to the FITC/biotin ﬂap substrate,
also known as hook point because at analyte concentra-
tions greater than the peak value the luminescence signal
decays due to saturation of the beads’ binding capacity,
was determined by substrate titration against the
anti-FITC-acceptor and streptavidin-donor AlphaScreen
beads (ﬁnal concentration 16mg/ml). An amount of 10ml
of 80mg/ml stock solution of anti-FITC-acceptor and
streptavidin-donor AlphaScreen beads was added to 40ml
of FITC/biotin ﬂap substrate in 384-well solid white plate
and incubated for 20min at room temperature. Plates were
read on EnVision plate reader (PerkinElmer) equipped
with AlphaScreen optical detection module. After deter-
mination of the hook point, the biotin/FITC
double-labeled substrate (1nM) was blended with its un-
labeled counterpart to produce a 50nM ﬁnal concentra-
tion, hereinafter referred to as AlphaScreen substrate. All
further assay optimization in the 384-well format was
carried out in a total reaction volume of 40ml. Brieﬂy,
30ml of FEN1 at the appropriate concentration or buffer
(no-enzyme control) was added into a 384-well plate; sub-
sequently, 10ml of substrate was added to initiate the en-
zymatic reaction which was then allowed to proceed for the
necessary time. AlphaScreen signal was measured 20min
after addition of 10ml bead homogenate containing 80mg/
ml each of streptavidin-coated donor beads and anti-FITC
antibody-coated acceptor beads.
The AlphaScreen assay was further miniaturized to a
ﬁnal volume of 5ml in the 1536-well format. Threemlo f
FEN1 was dispensed into a 1536-well plate and test com-
pounds were delivered as 23-nl aliquots of DMSO solu-
tions via pintool transfer. The plate was incubated for
15min at room temperature, and after dispensing of 1ml
of substrate, the enzyme reaction was allowed to proceed
for 5min at room temperature. AlphaScreen beads were
then added and the signal was measured on EnVision
plate reader (PerkinElmer) after a 20-min incubation at
room temperature.
Determination of the FEN1 cleavage site
To determine the site of cleavage of the ﬂuorogenic sub-
strate, FEN1 (100nM) was incubated with the
double-ﬂap oligonucleotide substrate (50nM) for 15min
at room temperature ( 23 C) under the conditions used
for the HTS assay. Reactions were stopped, and DNAs
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Visualization was executed using a Typhoon 9410
Variable Mode Imager and the direct green-excited ﬂuor-
escence setting. In turn, the AlphaScreen assay substrate
(500nM) was incubated with FEN1 (30nM) for 15min
at room temperature ( 23 C) under the conditions used
for the HTS assay. Visualization was executed using a
standard UV light box. Control TAMRA- and
FITC-labeled oligodeoxynucleotides corresponding to a
range of possible cleavage fragments of the two sub-
strates (at the ﬂap position or one or more positions
upstream or downstream) were synthesized and
included on the gels as migration markers.
RESULTS
Fluorogenic FEN1 assay principle
We exploited the ability of FEN1 to process DNA sub-
strates containing double-ﬂap structures in order to
develop a kinetic ﬂuorogenic donor/quencher assay for
identiﬁcation of FEN1 inhibitors operating in the
red-shifted light detection spectral region. A
double-stranded DNA substrate containing a pair of
ﬂap strands was prepared from three oligodeoxy-
nucleotide strands as depicted in Figure 1. The 50-end
of the downstream ﬂap strand was labeled with
6-TAMRA as the ﬂuorophore donor, whereas the
30-end of the quencher ﬂap strand was labeled with a
BHQ-2 (Figure 1B). In order to maintain proximity
between the TAMRA label on the 50-ﬂap strand and
the BHQ-2 matching quencher on the adjacent ﬂap
strand, a ﬁve-base nucleotide stretch was designed to
provide complementarity between the 50-ﬂuorophore
region and 30-quencher region (bases directly adjacent
to the ﬂuorophore and quencher labels indicated by
dotted lines in Figure 1A). Upon ﬂap strand cleavage
by FEN1 of the annealed three stranded substrate, a
short single stranded product labeled with 6-TAMRA
is enzymatically released, causing the ﬂuorophore
emission to increase (Figure 1A).
Fluorogenic assay optimization and miniaturization
In an initial test, 50nM substrate was incubated in the
absence or presence of 20nM FEN1 in a 384-well plate
at a 40ml total reaction volume, with ﬂuorescence being
monitored as a function of reaction time (Figure 2A). The
assay signal increased with time only in the presence of
FEN1 and reached a 7-fold higher level relative to the
no-enzyme control. The DNA substrate was further
evaluated by recording the reaction progress at different
substrate concentrations (Figure 2B). The increase in sub-
strate supplied led to a direct increase in initial rate and in
ﬁnal signal amplitude, supporting multiple turnover for
the enzyme. From these data, a Km of 59±7nM was
A
B
C
Figure 1. Fluorogenic FEN1 assay. (A) FEN1 cleaves the 50-end of ﬂap strand of the substrate construct (broken arrow) to liberate a short
ﬂuorophore-labeled single-stranded fragment causing increased ﬂuorescence signal (denoted by gold ﬂash). Dotted line indicates region of comple-
mentarity between the 50-ﬂuorophore region and 30-quencher region; ﬂap length is indicated by the number in italics. F can be any ﬂuorophore, and
Q represents any compatible quench molecule. (B) Structures of the 6-TAMRA ﬂuorophore and BHQ-2 quencher used here. (C) Sequences of
template, quencher and ﬂap strands that make up the ﬂuorogenic assay DNA substrate. Colors correspond to substrate image depicted in (A).
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previously determined for this enzyme using a single ﬂap
substrate in a radiolabel-based assay (12,40), validating
the use of the present substrate construct. A substrate
concentration of 50nM was chosen for the subsequent
experiments. We selected a relatively high enzyme concen-
tration during these investigations as we wished to observe
the completion of the reaction within a relatively short
time frame, to avoid complications from reagent evapor-
ation in the microtiter plate. Lower enzyme concentra-
tions do produce signal, as well, but the corresponding
data collection (to attain the same change in ﬂuorescence)
requires longer reaction times and the dilute enzyme solu-
tions generally have lower overnight stability, making
large-scale high throughput screening difﬁcult (data not
shown). The new tripartite double-ﬂap substrate was
stable upon storage at  20 C and exhibited consistent
low ﬂuorescence upon repeated freeze-thaw cycles (data
not shown).
The ﬂuorogenic assay was miniaturized to a 4ml ﬁnal
volume. The assay protocol consisted of dispensing 3mlo f
enzyme solution into the plate, followed by the addition of
1ml substrate to start the reaction: a robust ﬂuorescence
intensity rise and low well-to-well variation were observed
(Figure 3A). Figure 3B demonstrates that the assay
reagents, as formulated as working stocks, were stable
over a 16h storage period with a high average assay Z0
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Figure 2. Demonstration of the ﬂuorogenic assay in 384-well plate
format. (A) The assay was run at room temperature by following the
ﬂuorescence signal in kinetic mode in the presence (20nM) or absence
of FEN1 protein over a 30-min time period (N=3, individual plots
from the triplicate experiments are shown and indicated by the numbers
in parentheses). Substrate concentration=50nM. (B) Fluorescence
signal as a function of time at different ﬂuorogenic substrate concen-
trations (averages and standard deviations from triplicate measure-
ments shown). (C) Kinetic data from Panel B plotted to estimate Km.
Initial rate data were ﬁtted to the Michaelis–Menten equation using
GraphPad Prism ver. 5.
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(A) Real-time reaction monitoring (N=264), with and without
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and the reagents were assayed periodically using the miniaturized assay
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based on assay signal window and standard deviation:
values >0.5 (maximum Z0 factor attainable is equal to
1.0) are indicative of a robust assay (41).
Chemiluminescence assay for FEN1 activity
A single-ﬂap DNA structure served as a template for the
design of the chemiluminescent substrate. In order to
install binding sites for the donor and acceptor beads,
the 50-end of the ﬂap strand was labeled with a ﬂuorescein
tag (ﬂuorescein isothiocyanate, FITC) and the adjacent
upstream strand was labeled with biotin at its 50-end
(Figure 4A). The 50-biotin moiety served as a recognition
point for the streptavidin-coated donor bead, while the
FITC label on the 50-end of the ﬂap strand was recognized
by an anti-ﬂuorescein antibody-coated acceptor bead.
Thus, intact substrate, when mixed with chemiluminescent
donor and acceptor beads, was expected to yield a high
signal, while FEN1-catalyzed ﬂap strand cleavage would
result in a decreased signal due to the separation of biotin
and ﬂuorescein tags. Inhibition of the FEN1 reaction
would result in a higher signal than the uninhibited
control.
We ﬁrst analyzed the beads’ binding capacity to the
FITC/biotin ﬂap substrate by titration against a mix of
anti-FITC-acceptor and streptavidin-donor AlphaScreen
beads in a 40ml total reaction volume. The
concentration-response curve (Figure 4B) exhibited a
maximum response  2nM followed by a signal decrease
to background levels as the substrate concentration was
further increased. This biphasic behavior (also referred to
as hook point) is characteristic of the AlphaScreen assay
format, as well as similar-format ELISA type immuno-
assays, and is due to the saturation of the beads’ binding
capacity. Only a background signal was detected when
the unlabeled version of the substrate (i.e. devoid of
biotin and FITC tags) was used (Figure 4B, empty tri-
angles), indicating that the detection signal was strictly
dependent upon the presence of the corresponding recog-
nition tags and that no detectable nonspeciﬁc bead-
substrate interaction was present. To attain a total sub-
strate concentration close to the Km value for FEN1 and
to more closely match the reaction conditions of the
ﬂuorogenic assay, the biotin/FITC double-labeled
reagent (1nM) was blended with its unlabeled counterpart
to produce a 50nM ﬁnal substrate concentration, akin
to the presence of only a small fraction of radiolabeled
(‘hot’) molecule in the background of excess unlabeled
(‘cold’) counterpart when conducting radiotracer-based
assays.
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Figure 4. Chemiluminescence-based Assay. (A) Schematic representation of the ﬂap DNA substrate; ﬂap length is indicated by the number in italics.
The three deoxyoligonucleotide sequences are shown. The biotin and ﬂuorescein (FITC) labels introduced for bead recognition are indicated on the
50-ends of the ﬂap and upstream strands, respectively. The FEN1 cleavage site is indicated by the broken arrow. Upon red-shifted light excitation
( 680) of the donor bead, singlet oxygen is generated. If singlet oxygen encounters an acceptor bead within its traveling range, it triggers the emission
of blue-shifted light from the acceptor bead ( 520–620). (B) Substrate titration against beads (N=2). A strong dose-dependent signal associated with a
‘hook-shaped’ curve was observed as expected (see text for details), in contrast to the unlabeled control (empty triangles), which elicited only a
background signal. (C) Concentration dependence of the cleavage reaction on FEN1 protein (N=2).
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on FEN1 enzyme, we performed a titration of FEN1
against 50nM substrate in a 384-well plate format in a
total volume of 40ml. The assay signal decreased in a
dose-dependent manner with increasing concentration of
FEN1 (Figure 4C), with ﬂap cleavage reaching completion
at  10nM protein (reaction signal became undistinguish-
able from that obtained with buffer background). The
optimal concentration for AlphaScreen FEN1 assay was
selected as 3nM, balancing the needs for ample signal
window and minimal substrate conversion.
The assay was further miniaturized to a ﬁnal volume of
4ml in 1536-well format. The enzyme reaction (3ml enzyme
dispensed into an empty well, 23nl inhibitor solution
added via pin-transfer as necessary, and 1ml substrate
addition initiating the reaction) was performed as
described in ‘Materials and Methods’ section. To
observe the AlphaScreen signal at the end of the enzymatic
reaction period, 1ml of bead mix was added and the signal
was measured after a 20-min bead incubation. A strong
signal window of over 8.0 (deﬁned as the signal ratio
between catalyzed and uncatalyzed reactions) and a
high Z0 factor of 0.89 were obtained (Supplementary
Figure S1).
Enzymatic processing of the ﬂuorogenic and
chemiluminescence substrates
To determine the site of cleavage of the present substrates,
we performed the FEN1 reactions and analyzed the
products by gel electrophoresis followed by gel imaging.
The reaction utilizing the ﬂuorogenic double-ﬂap sub-
strate was analyzed by ﬂuorescence gel imaging of the
TAMRA label and processing of the AlphaScreen
single-ﬂap substrate was monitored by detection of the
FITC-labeled ﬂap strand. Control TAMRA- and
FITC-labeled oligodeoxynucleotides corresponding to a
range of possible cleavage fragments (at the ﬂap position
or one or more positions upstream or downstream) were
synthesized and included on the gel as migration markers
(Figure 5). We found that both substrates are cleaved in
the presence of FEN1 in their corresponding ﬂap regions.
The cleavage position of double-ﬂap substrate is approxi-
mately two bases downstream of the ﬂap (Figure 5A),
while the incision point of the single-ﬂap chemilumines-
cence substrate is either one or two bases downstream
(Figure 5B).
During the above experiments, we observed that the
ﬂuorogenic double-ﬂap substrate was less preferred by
FEN1 than the chemiluminescence substrate, as the
reaction using the former required higher concentration
of enzyme compared with the latter (Figure 5). This is
consistent with the mechanism of FEN1 engagement of
its target DNA. Speciﬁcally, recent studies by Gloor
et al. (42) and Stewart et al. (43) have shown that the
enzyme ﬁrst recognizes the double-stranded DNA
portion of the substrate at the base of the ﬂap and then
threads the 50-ﬂap for cleavage, with the binding inter-
actions of FEN1 with the substrate’s ﬁrst base of the
30-ﬂap being a critical step in reaction initiation (44).
Furthermore, X-ray crystallographic evidence indicates
that FEN1 recognizes single nucleotide 30-ﬂaps and
makes several contacts with the sugar moiety of the
30-ﬂap, especially the free 30-hydroxyl terminus (45). The
present ﬂuorogenic substrate is less preferred because it
contains a multinucleotide 30-ﬂap and thus is unable to
facilitate key contacts with the 30-hydroxyl. Overall, the
ﬂuorophore/quencher-labeled double-ﬂap structure
presents more impediments to FEN1 binding (a long
30-ﬂap and both a donor and a quencher tag present at
the loading site) than the singly labeled single-ﬂap chemi-
luminescence substrate (no second/30-ﬂap and only one
label at the loading site).
Small molecule inhibitor investigations
There are only a few FEN1 inhibitors reported in the lit-
erature and most of these compounds are not commercial-
ly available. In order to assess the recently-reported
hydroxyurea-based inhibitors, we resynthesized
3-hydroxy-5-methyl-1-phenylthieno[2,3-d]pyrimidin-
e-2,4(1H,3H)-dione (PTPD) described in Tumey et al. (36)
(details on the preparation and characterization of PTPD
are available in Supplementary Data). When PTPD was
tested in each of the above assays, a strong
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Figure 5. FEN1 cleavage site. (A) HTS assay substrate. FEN1 was
incubated with the HTS oligonucleotide substrate as described in
‘Materials and Methods’ section. Reactions were stopped, and DNAs
were separated and visualized as described in the text; shown is a rep-
resentative gel image. Arrow denotes the site of FEN1 incision, which
appears to be around ‘+2’. NE=no enzyme control reaction with HTS
substrate. FLS=50-TAMRA-GA TGT CAA GCA GTC CTA ACT
TTG AGG CAG AGT CCG C-30; FLP=50-TAMRA-GA TGT CAA
GCA GTC CTA ACT-30; FLP-1=50-TAMRA-GA TGT CAA GCA
GTC CTA AC-30; FLP+1=50-TAMRA-GA TGT CAA GCA GTC
CTA ACT T-30.( B) AlphaScreen assay substrate. FEN1 was incubated
with the AlphaScreen substrate as described in ‘Materials and Methods’
section. Visualization was executed using a standard UV light box, and
shown is a representative gel image. Arrows denote the two sites of
incision, which appear to be around ‘+1’ and ‘+2’. See above for
further details. a-S=50-FITC-TTT TTT TTT TTT ATT CAT CAA
CTG ACA TCT CCT AC-30; a-P=50-FITC-TTT TTT TTT TTT-30;
a-P-1=50-FITC-TTT TTT TTT TT-30; a-P+1=50-FITC-TTT TTT
TTT TTT A-30.
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(Figure 6), with the present study revealing IC50 values
close to those reported originally (36). DMSO, a small
molecule frequently used as a solvent in inhibition
studies, was tested and found to not inhibit FEN1 at con-
centrations up to 0.67% (data not shown).
We next tested aurintricarboxylic acid (ATA), a
compound previously reported to be a broad-speciﬁcity
inhibitor of multiple classes of DNA-processing enzymes
(46,47), and a small set of compounds sharing the
arylstibonic core, which had recently been reported by
Seiple et al. (48) as inhibitors of the human abasic endo-
nuclease APE1. ATA inhibited FEN1 at submicromolar
potency and the IC50 values obtained in the two independ-
ent assays were nearly identical, indicating that the
ﬂuorogenic and AlphaScreen formats afforded similar
sensitivity to inhibitors (Figure 6 and Table 1). The
arylstibonic series yielded robust concentration-dependent
inhibition and a range of IC50 potencies (Figure 6). Again,
the IC50 values derived from the two assays showed very
little assay-to-assay variation (Table 1).
Lastly, to provide additional validation of the new
assays developed here, we tested four out of the six com-
pounds from above in a standard FEN1 assay with a
32P-labeled single-ﬂap substrate prepared as described pre-
viously (49). Robust concentration-dependent inhibition
was observed for the four compounds in the
32P-based
assay (Supplementary Figure S2); moreover, the rank
order of inhibitory potency was maintained across all
three assay platforms.
DISCUSSION
Recent studies have indicated a role for FEN1 in cancer
progression and therapeutic agent resistance, suggesting
that the protein might be a sound target in certain
anticancer treatment paradigms. However, simple
methods for monitoring FEN1 activity have been
lacking. Moreover, reliance on a single assay to discover
and develop inhibitors can lead to retention of undesired
false positives. Ideally, a second assay, operating at the
same level of biochemical complexity, but utilizing a dif-
ferent signal output, would be used to validate
previously-uncharacterized inhibitors. The present work
provides two simple homogeneous assays for monitoring
FEN1 activity and inhibition that operate under orthog-
onal principles. The ﬂuorogenic donor-quencher assay
follows the generation of reaction product in real time,
while the chemiluminescence-based assay monitors the
consumption of substrate using a simple ﬂap structure.
The selection of TAMRA as the assay ﬂuorophore
donor was driven primarily by the desire to place the de-
tection wavelength within a red-shifted region of the light
spectrum in order to avoid compound library
autoﬂuorescence which is dominant in the shorter wave-
length regions. BHQ-2 is a highly efﬁcient non-emitting
quencher whose absorption spectrum overlaps well with
the emission of TAMRA. Furthermore, both ﬂuorophore
Table 1. Small molecule inhibitors
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Figure 6. Small molecule inhibitor investigations. Concentration-
response plots for the molecules investigated using (A) the kinetic
ﬂuorogenic assay and (B) the chemiluminescence AlphaScreen assay
(N=2). Compound structures and IC50 values derived from these
plots are presented in Table 1.
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number of assays for DNA repair proteins and other
targets and have been used successfully in at least four
large-scale HTS campaigns [PubChem Assay IDs 2517,
1490, 2528 and 2549 and (50–52)].
The excellent stability of the ﬂuorogenic assay coupled
with a robust statistical performance in the 1536-well plate
format indicates that the assay can be deployed reliably.
The ability to collect kinetic data, allowing an assessment
of the rate of ﬂuorescence change, as opposed to collecting
endpoint data only, makes the assay signal less susceptible
to variations in liquid dispenser performance.
Furthermore, kinetic reads make it possible to ﬂag false
positive compounds which interfere with the light detec-
tion by autoﬂuorescence or quenching, as such com-
pounds will shift the starting well ﬂuorescence up or
down, but will have no effect on the rate of ﬂuorescence
change.
In turn, the AlphaScreen (Ampliﬁed Luminescence
Proximity Homogeneous Assay) assay uses a bead-based
chemistry combined with chemiluminescence detection in
order to detect low concentrations of analyte. Due to their
colloidal size and properties, AlphaScreen beads are con-
veniently processed by liquid dispensers in the same
manner as regular homogeneous reagents. Upon excita-
tion with 680-nm light, reagents embedded within the
donor bead generate singlet oxygen, which diffuses in
solution within its short lifetime. If an acceptor bead is
within close proximity (200nm), the singlet oxygen
triggers light emission in the 520- to 620-nm range from
rubrene contained within that bead. In the FEN1 assay
described herein, AlphaScreen is used in a ‘reverse’ mode
to monitor the decrease of the substrate analyte: inhibition
of the enzymatic reaction is being detected as a signal gain
relative to uninhibited reaction control, making this assay
conﬁguration particularly resistant to interference from
signal quenchers, such as intensely colored substances
and singlet oxygen scavengers.
To validate our pair of newly developed FEN1 assays,
we tested a dose response of PTPD, a previously-reported
inhibitor (36), which was resynthesized for the present
study. The compound displayed similar potency in the
present assays as reported earlier, thus validating the
set-up developed here. To extend the present methodology
to additional small molecules, we tested a dose response of
ATA, a compound previously reported to be a broad-
speciﬁcity inhibitor of multiple classes of DNA-processing
enzymes such as polymerases and nucleases. For example,
in our previous studies, ATA displayed potent inhibition
against Tdp1 (53), the DNA polymerases beta, eta and
iota (50), and against the major abasic endonuclease
APE1 (51). Thus, we wished to ascertain whether such a
generic inhibitor will suppress FEN1 activity, and if it did,
whether its inhibitory potency will be similar across the
two assay methods under consideration. As anticipated,
ATA inhibited FEN1 at submicromolar potency; further-
more, the IC50 values obtained in the two independent
assays were nearly identical, indicating that the
ﬂuorogenic and AlphaScreen formats afforded similar
sensitivities to inhibitors.
Lastly, we tested a small set of structurally-related com-
pounds (based on the arylstibonic core), which had
recently been reported as inhibitors of APE1, the main
enzyme for repairing abasic sites within the genome (48).
These APE1 inhibitors were found to inhibit FEN1, as
well: notably, the IC50 values derived herein against
FEN1 showed very little assay-to-assay variation, despite
the differences in the assay format (detection modality, as
well as different sequence and structure of the ﬂap sub-
strate). Moreover, the inter-assay concordance of IC50
values remained good within a broad range of inhibitor
potencies (including the region above the maximum
compound concentration tested where lack of
high-concentration data made curve ﬁtting less robust
and where only extrapolated IC50 values could be
obtained), indicating that the present two assays are not
only capable of detecting a wide range of compound
potencies, but are also equally sensitive to inhibition
across that broad potency range. Furthermore, the com-
parative testing of the four inhibitors using the radiogel
method served as additional validation of the new assays
presented here.
In summary, we describe two homogeneous assays to
enable investigations of FEN1 enzymatic activity that
should be easily adaptable to other enzymes capable of
processing similar DNA structures. Unique features of
each format include the ability to collect kinetic data
with the ﬂuorogenic assay and the high signal and insensi-
tivity to autoﬂuorescence of the chemiluminescence
method. We anticipate the ﬂuorogenic method to be
used for most enzymological and inhibitor investigations,
with the AlphaScreen counterpart being deployed when
newly-discovered inhibitors need to be validated by an
orthogonal readout approach.
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